Evidence map›Paper›PMID 39828449›Full record

ArticleJournal of geriatric oncology2025

Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3.

Kah Poh Loh, Qiao Ming Rachel Ng, Supriya G Mohile, Sally Norton, Ronald M Epstein, Michael B Sohn, Daniel Richardson, Omer Jamy, Soroush Mortaz Hedjri, Rachel Blumberg and 12 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of geriatric oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kah Poh LohJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: kahpoh_loh@urmc.rochester.edu.
Qiao Ming Rachel NgDuke-NUS Medical School, Singapore; Department of Geriatric Medicine, Singapore General Hospital, Outram Road, Singapore. Electronic address: rachel.ng.q.m@singhealth.com.sg.
Supriya G MohileJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: supriya_mohile@urmc.rochester.edu.
Sally NortonSchool of Nursing, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: sally_norton@urmc.rochester.edu.
Ronald M EpsteinJames P. Wilmot Cancer Institute, Rochester, New York, USA; Department of Family Medicine, University of Rochester Medical Center, Rochester, New York, USA; Department of Medicine (Palliative care), University of Rochester Medical Center, Rochester, New York, USA. Electronic address: ronald_epstein@urmc.rochester.edu.
Michael B SohnDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: michael_sohn@urmc.rochester.edu.
Daniel RichardsonDivision of Hematology, University of North Carolina Lineberger Comprehensive Cancer Center, NC, USA. Electronic address: daniel_richardson@med.unc.edu.
Omer JamyDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, USA. Electronic address: omerjamy@uabmc.edu.
Soroush Mortaz HedjriJames P. Wilmot Cancer Institute, Rochester, New York, USA. Electronic address: Soroush_MortazHedjri@urmc.rochester.edu.
Rachel BlumbergJames P. Wilmot Cancer Institute, Rochester, New York, USA. Electronic address: Rachel_blumberg@urmc.rochester.edu.
Laura NafisJames P. Wilmot Cancer Institute, Rochester, New York, USA. Electronic address: Laura_nafis@urmc.rochester.edu.
Marielle Jensen-BattagliaDepartment of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: Marielle_JensenBattaglia@urmc.rochester.edu.
Ying WangDepartment of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Electronic address: ying_wang@urmc.rochester.edu.
Jason MendlerJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: Jason_mendler@urmc.rochester.edu.
Jane LiesveldJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: Jane_liesveld@urmc.rochester.edu.
Eric J HuseltonJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: Eric_huselton@urmc.rochester.edu.
Rachel RodenbachJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: Rachel_rodenbach@urmc.rochester.edu.
Jozal MooreJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: Jozal_moore@urmc.rochester.edu.
Craig MaguireJames P. Wilmot Cancer Institute, Rochester, New York, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: Craig_maguire@urmc.rochester.edu.
Steve M BuechlerMyeloid Cancer Advisory Board. Electronic address: steve.buechler@mnsu.edu.
Steve HodgesMyeloid Cancer Advisory Board.
Heidi D KlepinSection of Hematology/Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, NC, USA. Electronic address: hklepin@wakehealth.edu.

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Geriatric Oncology Research Infrastructure to Improve Clinical CareR33AG059206 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE, Heidi Diana Klepin · 2020 to 2026
$5.1M
A Patient-Oriented Research Program in Geriatric OncologyK24AG056589 · NIA · UNIVERSITY OF ROCHESTER · PI Supriya G. Mohile · 2018 to 2026
$1.5M
A decisional intervention for older adults with acute myeloid leukemia and their caregiversR01CA288318 · NCI · UNIVERSITY OF ROCHESTER · PI Kah Poh Loh · 2025 to 2026
$1.3M
A novel mobile health exercise intervention for older patients with myeloid neoplasmsR00CA237744 · NCI · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2021 to 2023
$747k
NCI NIH HHS R00 CA237744NCI NIH HHS R01 CA288318NCI NIH HHS UG1 CA189961NIA NIH HHS K24 AG056589NIA NIH HHS R33 AG059206
6 · The paper itself

Abstract

introductionTherapeutic advances have allowed more adults aged ≥60 years with acute myeloid leukemia (AML) to receive life-prolonging treatments, with improvement in overall survival. In contrast to other cancers, the onset of AML is often sudden, high-risk treatment decisions must be made quickly, and survival is often compromised due to aging-related conditions (e.g., functional impairments). Studies have demonstrated that up to 78 % of older adults with AML and their caregivers experience significant psychological distress. Distress is associated with poor quality of life, increased healthcare utilization, and increased mortality. Shared decision making (SDM) can reduce patient and caregiver distress and is essential to achieve goal-concordant care. Therefore, interventions to alleviate distress and optimize SDM in older adults with AML and their caregivers are needed. We will conduct a multicenter randomized controlled trial to evaluate the efficacy of University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL) compared to an attention control for reducing patient distress and improving observed SDM, patient-perceived SDM, and decisional conflict. MATERIAL AND

methodsWe will recruit 300 patients aged ≥60 years with newly diagnosed AML, their caregivers (one caregiver per patient when available), and up to 40 oncologists from four institutions: (1) Patients will view an educational video about AML diagnosis, treatment, and prognosis; complete the Best Worst Scaling values clarification process; and review a summary report of their values with tailored question prompts and resources; (2) Caregivers will view the same educational video and receive the same summary report as patients; and (3) Oncologists will review a summary report of the patient's aging-related conditions, perception of prognosis, and values. Patients, caregivers, and oncologists will then meet during clinical visits to discuss aging-related conditions, prognosis, and patient values, and reach a treatment decision. The primary outcome measure is distress (Distress Thermometer). Secondary outcome measures include observed SDM, patient perceived SDM, and decisional conflict. DISCUSSION: This study will address significant knowledge gaps related to reducing distress and decisional conflict and improving SDM in older adults with AML. If successful, this research will inform future decisional interventions for a broader group of patients.

Indexed as

CaregiversDecision Making, SharedLeukemia, Myeloid, AcuteAgedAged, 80 and overDecision MakingFemaleHumansMaleMiddle AgedMulticenter Studies as TopicPsychological DistressQuality of LifeRandomized Controlled Trials as TopicAcute myeloid leukemiaGeriatric assessmentGeriatric hematologyPerception of prognosisShared decision makingValues clarification

Identifiers

PMID39828449
PMCPMC11890953

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.